Product Image

Contributor Information

  • Name Richard Ferrero
  • Institute Hudson Institute of Medical Research

Tool Details

  • Tool name: Human AGS NOD1 KO (Clone 41A8) Cell Line
  • Alternate names: Human nucleotide-binding oligomerization domain-containing protein 1, NOD1.
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: AGS
  • Organism: Human
  • Tissue: Gastric
  • Cancer type: Digestive / Gastrointestinal cancer
  • Disease: Cancer
  • Growth properties: Epithelial-like morphology
  • Model: Knock-Out
  • Conditional: No
  • Description: NOD1 responds to Helicobacter pylori infection in a Type IV secretion system-dependent manner. H. pylori causes chronic inflammation, a key precursor to gastric adenocarcinoma. AGS cells deficient in NOD1 (as generated by CRISPR) can be used to model gastric adenocarcinoma in the context of various pathogens. NOD1 regulates host epithelial cell responses. Upregulates antimicrobial peptides of the beta-defensin (hBD) family secreted by epithelial cells.
  • Research area: Cancer; Cell signaling and signal transduction; Immunology
  • Production details: CRISPR/Cas9 gene editing was used to generate NOD1 knock out clones. AGS cells were transfected with vectors expressing â?‚€?‚ÂœCas9 nickaseâ?‚€?‚ nuclease and pairs of guide RNAs (gRNAs) specific for the NOD1 gene. Clone 41A8 was confirmed as having a 71 base pair deletion within the coding regions of the caspase activation and recruitment domain (CARD) of NOD1. Recommended Freezing Composition: 90% (v/v) FCS - 10% (v/v) DMSO
  • Additional notes: Recommended Freezing Composition: 90% (v/v) FCS - 10% (v/v) DMSO CRISPR edited Human AGS cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license. The control Human AGS Control Cell Line can be purchased from ATCC http://www.lgcstandards-atcc.org/products/all/CRL-1739.aspx?geo_country=gb.

  • For Research Use Only

Target Details

  • Target: Human nucleotide-binding oligomerization domain-containing protein 1

Application Details

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license

Handling

  • Format: Frozen
  • Growth medium: RPMI with: 10% foetal calf serum; 1% penicillin-streptomycin; and 1% L-glutamine. Subculture cells every 2-3 days in ratios of 1:2-1:4 in T25 or T75 flasks.
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

References

  •   Tran et al. 2018. Cell Microbiol. 20(5):e12826. PMID: 29392836.
  •   NOD1 is required for Helicobacter pylori induction of IL-33 responses in gastric epithelial cells.